Tiered Fixed-Dose Plerixafor Resulted in Enhanced CD34+ Cell Mobilization and Collection with a Comparable Safety Profile Versus Weight-Based Plerixafor in Patients with Sickle Cell Disease: Results from the Ongoing BEACON Study of Autologous CD34+ Base-Edited Hematopoietic Stem Cells (BEAM-101)